COI Publications

COI Affiliated Publications (First author/ Corresponding author)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.

Costa Clemens SA. et al, (2022), Lancet (London, England)

Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers

Wang W. et al, (2021), Journal of Biological Rhythms, 074873042110593 - 074873042110593

An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

Peng Y. et al, (2022), Nature Immunology, 23, 50 - 61

Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences

Lee JY. et al, (2022), eLife, 11

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2021)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Dejnirattisai W. et al, (2021), Lancet (London, England)

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.

Liu C. et al, (2022), Cell host & microbe, 30, 53 - 68.e12

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire

Swanson PA. et al, (2021), Science Translational Medicine

The impact of viral mutations on recognition by SARS-CoV-2 specific T cells

de Silva TI. et al, (2021), iScience, 24, 103353 - 103353

Priority index: database of genetic targets in immune-mediated disease.

Fang H. and Knight JC., (2021), Nucleic Acids Res

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.

Zhuang X. et al, (2021), bioRxiv

Immunodominance complexity: lessons yet to be learned from dominant T cell responses to SARS-COV-2

Wellington D. et al, (2021), Current Opinion in Virology, 50, 183 - 191

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Flaxman A. et al, (2021), The Lancet, 398, 981 - 990

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu C. et al, (2021), Cell, 184, 4220 - 4236.e13

Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells

Wing PAC. et al, (2021), Cell Reports, 35, 109020 - 109020

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Townsend A. et al, (2021), Nature Communications, 12

Host genetics and infectious disease: new tools, insights and translational opportunities

Kwok AJ. et al, (2020), Nature Reviews Genetics

IFITM3-specific antibody reveals IFN preferences and slow IFN induction of the antiviral factor IFITM3 in humans.

Wellington D. et al, (2021), European journal of immunology, 51, 742 - 745

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Dejnirattisai W. et al, (2021), Cell, 184, 2183 - 2200.e22

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6

DUB esterase activity further decodes ubiquitin’s enigma

Kessler BM., (2021), Proceedings of the National Academy of Sciences, 118, e2026389118 - e2026389118

Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.

Pinto-Fernandez A. et al, (2020), British journal of cancer

Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities

Liang Z. et al, (2021), Cell Communication and Signaling, 19

Clocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic.

Sengupta S. et al, (2021), Journal of biological rhythms, 36, 23 - 34

Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter

Wing PAC. et al, (2021), Journal of Hepatology

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.

Tan TK. et al, (2021), Nature communications, 12

Malignancy and IFITM3: Friend or Foe?

Rajapaksa US. et al, (2020), Frontiers in oncology, 10

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Peng Y. et al, (2020), Nature Immunology, 21, 1336 - 1345

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

Zhou D. et al, (2020), Nature Structural & Molecular Biology, 27, 950 - 958

Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.

Zhao Y. et al, (2020), JCI insight

Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient.

Abd Hamid M. et al, (2020), Cellular & molecular immunology

Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019

Zhang Y. et al, (2020), The Journal of Infectious Diseases

A Novel Scoring System for Prediction of Disease Severity in COVID-19.

Zhang C. et al, (2020), Frontiers in cellular and infection microbiology, 10

Defective Interferon Gamma Production by Tumor-Specific CD8+ T Cells Is Associated With 5′Methylcytosine-Guanine Hypermethylation of Interferon Gamma Promoter

Abd Hamid M. et al, (2020), Frontiers in Immunology, 11

Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses

Abd Hamid M. et al, (2020), Cancer Immunology Research, 8, 203 - 216

Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.

Rijal P. et al, (2020), Journal of virology, 94

A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer

Li X. et al, (2019), Frontiers in Oncology, 9

Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses

Abd Hamid M. et al, (2019), Cancer Immunology Research, 7, 1293 - 1306

IFITM3: How genetics influence influenza infection demographically.

Wellington D. et al, (2019), Biomedical journal, 42, 19 - 26

COI Affiliated Publications (non-first author/ corresponding author)

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Stuart ASV. et al, (2022), Lancet (London, England), 399, 36 - 49

Why do breakthrough COVID-19 infections occur in the vaccinated?

Maclean P. et al, (2021), QJM : monthly journal of the Association of Physicians

HIF1α-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.

Riedl T. et al, (2021), Hepatology (Baltimore, Md.)

Promises and challenges of adoptive T-cell therapies for solid tumours

AHMED A. et al, (2021), British Journal of Cancer

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Ogbe A. et al, (2021), Nature Communications, 12

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.

Watanabe Y. et al, (2021), ACS central science, 7, 594 - 602

Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation

Berthold D., (2021), Nature Communications

Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka.

Jeewandara C. et al, (2021), J Immunol

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Skelly DT. et al, (2021), Nature Communications, 12

Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication*.

Melidis L. et al, (2021), Angewandte Chemie (International ed. in English), 60, 18144 - 18151

Reactivation of a developmentally silenced embryonic globin gene.

King AJ. et al, (2021), Nat Commun, 12

Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation.

Asciak R. et al, (2021), Frontiers in oncology, 11

HLA-E-restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities.

Yang H. et al, (2021), Sci Immunol, 6

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Ainsworth M. et al, (2020), The Lancet Infectious Diseases, 20, 1390 - 1400

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments

Kanellakis NI. et al, (2020), Thorax, 75, 1004 - 1008

Ubiquitomics: An Overview and Future

Vere G. et al, (2020), Biomolecules, 10, 1453 - 1453

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Huo J. et al, (2020), Nature Structural & Molecular Biology, 27, 846 - 854

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Huo J. et al, (2020), Cell Host & Microbe, 28, 445 - 454.e6

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)

Folegatti PM. et al, (2020), LANCET, 396, 466 - 466

Clinical and epidemiological features of COVID-19 family clusters in Beijing, China.

Song R. et al, (2020), The Journal of Infection

Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.

Kanellakis NI. et al, (2019), BMJ open respiratory research, 6

Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study.

Lindsey BB. et al, (2019), The Lancet. Respiratory medicine, 7, 665 - 676

Composition and structure of synaptic ectosomes exporting antigen receptor linked to functional CD40 ligand from helper T cells

Saliba DG. et al, (2019), eLife, 8

Single-Molecule, Super-Resolution, and Functional Analysis of G Protein-Coupled Receptor Behavior Within the T Cell Immunological Synapse.

Felce JH. et al, (2020), Front Cell Dev Biol, 8

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

COI Affiliated Publications—Preprints (first/corresponding author)

Absolute quantitation of individual SARS-CoV-2 RNA molecules: a new paradigm for infection dynamics and variant differences

Lee JY. et al, (2021)

Cookies on this website

COI Affiliated Publications (First author/ Corresponding author)

COI Affiliated Publications (non-first author/ corresponding author)

COI Affiliated Publications—Preprints (first/corresponding author)